Bard Acquires Certain Assets of Genyx Medical.MURRAY HILL, N.J. -- C. R. Bard C. R. Bard, Inc. (NYSE: BCR) is one of the large S&P 500 companies of the United States, a surgical specialties and hospital medical device manufacturer in Murray Hill, New Jersey. It is named after its founder, who sold the company within only a few years of its founding. , Inc. (NYSE NYSE See: New York Stock Exchange :BCR BCR B Cell Receptor BCR Business Communications Review (magazine) BCR Banca Comerciala Romana (Romanian bank) BCR Breakpoint Cluster Region BCR Benefit/Cost Ratio BCR Bay City Rollers ) today announced that it has acquired certain assets of Genyx Medical, Inc., of Aliso Viejo, California Aliso Viejo is a city in Orange County, California, United States. As of the 2000 census, Aliso Viejo population was 40,166. Aliso Viejo became Orange County's 34th city on July 1, 2001, and has been the only city in Orange County to incorporate since 2000. , related to the Uryx(R) implantable bulking agent for the treatment of stress urinary incontinence stress urinary incontinence n. See stress incontinence. . Bard acquired the right to purchase these assets from Genyx in December 2002. The Uryx product has received pre-market approval from the U.S. Food and Drug Administration and Bard anticipates its launch in the first half of 2005. The company's Urological division, located in Covington, Georgia, will market the product. Stress urinary incontinence is an often debilitating de·bil·i·tat·ing adj. Causing a loss of strength or energy. Debilitating Weakening, or reducing the strength of. Mentioned in: Stress Reduction condition that affects an estimated 50 million people globally, 85 percent of whom are women. Minimally invasive bulking agent therapy can be a first line treatment choice and is often used for patients who are not candidates for surgery. The Uryx product is a proprietary polymer implanted into the tissue surrounding the urethra urethra (y  rē`thrə), canal in most mammals that carries urine from the bladder to the outside of the body; in the male it also serves as a genital duct. to reduce or eliminate this form of urinary incontinence. Timothy M. Ring, chairman and chief executive officer, commented, "With the aging population and the increasing demand for more effective, minimally-invasive therapies for stress urinary incontinence, we view this acquisition as an important opportunity for Bard. We believe that the addition of the Uryx device will further strengthen our broad product line and enhance our position in the incontinence market." C. R. Bard, Inc. (www.crbard.com), headquartered in Murray Hill, N.J., is a leading multinational developer, manufacturer, and marketer of innovative, life-enhancing medical technologies in the fields of vascular, urology, oncology and surgical specialty products. This press release may contain forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. Please refer to our September 30, 2004 10-Q for a statement with regard to forward-looking statements, including disclosure of the factors that could cause actual results to differ materially from those expressed or implied. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion